Immunotherapy for Multiple Myeloma

Dear Colleagues,

Multiple myeloma (MM) is a genetically heterogenous disease that remains mostly incurable, with a small group of patients achieving long-term disease remission. In recent decades, we have witnessed unprecedented progress in the diagnostics and treatment of MM, particularily the advent of immunotherapeutic technologies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. Currently, CAR-T therapy is approved for relapsed refractory MM, with several ongoing studies investigating its application in earlier lines of therapy including an upfront setting. Despite the impressive response in heavily pre-treated patients, we are now faced with several challenges including access to therapies, requirements for specialized setup for production and administration of CAR-T, management of toxicities, lack of predictive biomarkers and refractory disease. There is a pressing need for clinical and translational research addressing these concerns. This Special Issue reflects the recent developments in immunotherapy, working toward transforming myeloma into a curable disease.

Dr. Meera Mohan
Dr. Carolina D. Schinke
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.